Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sun, Yue Li ^a,b   Chen, Jun Jiang ^b,c   Kumar, Priyank ^b   Chen, Kang ^d,e   Sodani, Kamlesh ^b   Patel, Atish ^b   Chen, Yang Lu ^b,f   Chen, Si Dong ^c   Jiang, Wen Qi ^a   Chen, Zhe Sheng ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b ST JOHN'S UNIVERSITY   (United States)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f Montgomery High School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 7; PACLITAXEL; TARIQUIDAR; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; MOLECULAR DYNAMICS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS;

CELL LINE; DRUG RESISTANCE, MULTIPLE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; QUINOLINES;

EID: 84873498417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055576     Document Type: Article

References (51)

1. Choi CH, (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5: 30.
2. Dassa E, Bouige P, (2001) The ABC of ABCS: a phylogenetic and functional classification of ABC systems in living organisms. Res Microbiol 152: 211-229.
3. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
4. Sharom FJ, (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9: 105-127.
5. Kimura Y, Morita SY, Matsuo M, Ueda K, (2007) Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98: 1303-1310.
6. Higgins CF, (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446: 749-757.
7. Dean M, Rzhetsky A, Allikmets R, (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166.
8. Dean M, Allikmets R, (2001) Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33: 475-479.
9. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD, (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64: 4927-4930.
10. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, et al. (2003) Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 63: 351-358.
11. Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, et al. (2008) MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 7: 1150-1155.
12. Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, et al. (2011) Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res 71: 3649-3657.
13. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS, (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12: 570-594.
14. Robert J, Jarry C, (2003) Multidrug resistance reversal agents. J Med Chem 46: 4805-4817.
15. Ahmed-Belkacem A, Pozza A, Macalou S, Perez-Victoria JM, Boumendjel A, et al. (2006) Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anticancer Drugs 17: 239-243.
16. Leonard GD, Fojo T, Bates SE, (2003) The role of ABC transporters in clinical practice. Oncologist 8: 411-424.
17. Ferry DR, Traunecker H, Kerr DJ, (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070-1081.
18. Klinkhammer W, Muller H, Globisch C, Pajeva IK, Wiese M, (2009) Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. Bioorg Med Chem 17: 2524-2535.
19. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, et al. (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128: 403-411.
20. Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, et al. (2009) A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 50: 1954-1961.
21. Kuhnle M, Egger M, Muller C, Mahringer A, Bernhardt G, et al. (2009) Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 52: 1190-1197.
22. Kannan P, Shukla S, Ambudkar SV, Pike VW, Halldin C, et al. (2011) The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci 2: 82-89.
23. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB, (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942.
24. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, et al. (2006) Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5: 39-47.
25. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, et al. (1999) Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9: 595-600.
26. Muller H, Pajeva IK, Globisch C, Wiese M, (2008) Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem 16: 2448-2462.
27. Pajeva IK, Wiese M, (2009) Structure-activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J 11: 435-444.
28. Smith AJ, Mayer U, Schinkel AH, Borst P, (1998) Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst 90: 1161-1166.
29. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, et al. (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61: 749-758.
30. Twentyman PR, Reeve JG, Koch G, Wright KA, (1990) Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin). Br J Cancer 62: 89-95.
31. Wang M, Zheng DX, Luo MB, Gao M, Miller KD, et al. (2010) Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2). Appl Radiat Isot 68: 1098-1103.
32. Bauer F, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, et al. (2010) Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem 18: 5489-5497.
33. Kawamura K, Konno F, Yui J, Yamasaki T, Hatori A, et al. (2010) Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med 24: 403-412.
34. Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo MT, et al. (2004) Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J Exp Ther Oncol 4: 239-246.
35. Malofeeva EV, Domanitskaya N, Gudima M, Hopper-Borge EA, (2012) Modulation of the ATPase and Transport Activities of Broad-Acting Multidrug Resistance Factor ABCC10 (MRP7). Cancer Res.
36. Wang P, Zhang Z, Gao K, Deng Y, Zhao J, et al. (2009) [Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi 12: 875-878.
37. Borel F, Han R, Visser A, Petry H, van Deventer SJ, et al. (2012) Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55: 821-832.
38. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, et al. (2012) The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27: 187-196.
39. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, et al. (2009) Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 69: 178-184.
40. Pick A, Wiese M, (2012) Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. ChemMedChem 7: 650-662.
41. Goler-Baron V, Sladkevich I, Assaraf YG, (2012) Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol 83: 1340-1348.
42. Yu XH, Jiang HL, Chen WJ, Yin K, Zhao GJ, et al. (2012) Interleukin-18 and interleukin-12 together downregulate ATP-binding cassette transporter A1 expression through the interleukin-18R/nuclear factor-kappaB signaling pathway in THP-1 macrophage-derived foam cells. Circ J 76: 1780-1791.
43. Hubensack M, Muller C, Hocherl P, Fellner S, Spruss T, et al. (2008) Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134: 597-607.
44. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, et al. (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17: 569-580.
45. Menefee ME, Fan C, Edgerly M, Draper D, Chen C, et al. (2005) Tariquidar (XR9576) is a potent and effective P-glycoprotein (Pgp) inhibitor that can be administered safely with chemotherapy. Journal of Clinical Oncology 23: 3093.
46. Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, et al. (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15: 3574-3582.
47. Walker J, Martin C, Callaghan R, (2004) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40: 594-605.
48. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, et al. (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6: 4186-4191.
49. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, et al. (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104: 682-691.
50. Fox E, Bates SE, (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7: 447-459.
51. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, et al. (2012) Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett 328: 307-317.